Evidence map›Paper›PMID 30627694›Full record

ArticleJNCI cancer spectrum2018

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Jennifer L Caswell-Jin, Sylvia K Plevritis, Lu Tian, Christopher J Cadham, Cong Xu, Natasha K Stout, George W Sledge, Jeanne S Mandelblatt, Allison W Kurian

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 177 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 8 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04280536 phase1 / phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

TypeinterventionalSponsorNational University Hospital, SingaporeRan2019 to 2026Enrolled86ConditionsBreast CancerArmsCohort A, Cohort B
NCT04520269 phase1 / phase2active not recruitingnot on this mapstarted 2020, after this paper: background citation

A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 (IRAK1) Pathway Activation (PAIR)

TypeinterventionalSponsorNational University Hospital, SingaporeRan2020 to 2026Enrolled74ConditionsBreast CancerArmsPacritinib
NCT05491083 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)

TypeinterventionalSponsorNational University Hospital, SingaporeRan2023 to 2026Enrolled51ConditionsAdvanced Solid Tumor, Triple Negative Breast CancerArmsPembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 8 syntheses or guidelines pooled it, 324 citations in OpenAlex.

  1. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Pegylated liposomal doxorubicin (DuomeisuBreast cancer research and treatment · 2023
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jennifer L Caswell-JinDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Sylvia K PlevritisDepartment of Biomedical Data Science, Department of Radiology, Stanford University School of Medicine, Stanford, CA.
Lu TianDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, CA.
Christopher J CadhamDepartment of Oncology, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Washington, DC.
Cong XuDepartment of Biomedical Data Science, Department of Radiology, Stanford University School of Medicine, Stanford, CA.
Natasha K StoutDepartment of Population Health, Harvard Pilgrim Health Care, Boston, MA.
George W SledgeDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Jeanne S MandelblattDepartment of Oncology, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Washington, DC.
Allison W KurianDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Stanford University · USGeorgetown University · USGeorgetown University Medical Center · USHarvard Pilgrim Health Care · US

Funding

Comparative Modeling: Informing Breast Cancer Control Practice and PolicyU01CA199218 · NCI · GEORGETOWN UNIVERSITY · PI BERRY, DONALD A, DE KONING, HARRY J · 2015 to 2019
$9.0M
Comparative Modeling: Informing Breast Cancer Control Practice & PolicyU01CA152958 · NCI · GEORGETOWN UNIVERSITY · PI BERRY, DONALD A, DE KONING, HARRY J · 2010 to 2015
$7.6M
Bio-behavioral Research At The Intersection of Cancer and AgingR35CA197289 · NCI · GEORGETOWN UNIVERSITY · PI MANDELBLATT, JEANNE · 2015 to 2021
$6.2M
NCI NIH HHS R35 CA197289NCI NIH HHS U01 CA152958NCI NIH HHS U01 CA199218
6 · The paper itself

Abstract

backgroundMetastatic breast cancer (MBC) treatment has changed substantially over time, but we do not know whether survival post-metastasis has improved at the population level.

methodsWe searched for studies of MBC patients that reported survival after metastasis in at least two time periods between 1970 and the present. We used meta-regression models to test for survival improvement over time in four disease groups: recurrent, recurrent estrogen (ER)-positive, recurrent ER-negative, and de novo stage IV. We performed sensitivity analyses based on bias in some studies that could lead earlier cohorts to include more aggressive cancers.

resultsThere were 15 studies of recurrent MBC (N = 18 678 patients; 3073 ER-positive and 1239 ER-negative); meta-regression showed no survival improvement among patients recurring between 1980 and 1990, but median survival increased from 21 (95% confidence interval [CI] = 18 to 25) months to 38 (95% CI = 31 to 47) months from 1990 to 2010. For ER-positive MBC patients, median survival increased during 1990-2010 from 32 (95% CI = 23 to 43) to 57 (95% CI = 37 to 87) months, and for ER-negative MBC patients from 14 (95% CI = 11 to 19) to 33 (95% CI = 21 to 51) months. Among eight studies (N = 35 831) of de novo stage IV MBC, median survival increased during 1990-2010 from 20 (95% CI = 16 to 24) to 31 (95% CI = 24 to 39) months. Results did not change in sensitivity analyses.

conclusionBy bridging studies over time, we demonstrated improvements in survival for recurrent and de novo stage IV MBC overall and across ER-defined subtypes since 1990. These results can inform patient-doctor discussions about MBC prognosis and therapy.

Identifiers

PMID30627694
PMCPMC6305243
OpenAlexW2905887518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.